Vivos Therapeutics, Inc.

https://vivos.com

Vivos Therapeutics, Inc. is a medical technology company dedicated to developing and commercializing diagnostic and treatment modalities for patients suffering from sleep-disordered breathing (SDB), including obstructive sleep apnea (OSA) and snoring. The company's mission is to provide clinically effective, non-surgical, non-invasive, non-pharmaceutical, and cost-effective solutions to improve breathing and sleep. Headquartered in Littleton, Colorado, Vivos Therapeutics aims to address the root causes of these conditions.

The company's core offering is The Vivos Method, a multidisciplinary treatment protocol that utilizes customized oral appliances. Key products include the Vivos CARE oral appliance therapy, encompassing DNA, mRNA, and mmRNA appliances. These devices are FDA 510(k) cleared for treating mild-to-severe OSA in adults, with the DNA appliance also cleared for moderate-to-severe pediatric OSA in children aged 6-17. Vivos also provides diagnostic tools like the VivoScore Program for at-home sleep testing, and services such as the Vivos Airway Intelligence Service (AIS) and Vivos Billing Intelligence Service (BIS).

Under the leadership of Chairman and CEO R. Kirk Huntsman, Vivos Therapeutics has recently focused on expanding its market reach through strategic acquisitions and collaborations. Notable developments include the acquisition of The Sleep Center of Nevada in June 2025, marking a pivot towards integrated sleep-center care and direct patient treatment. The company also reported a 16% increase in full-year 2025 revenue compared to 2024 and completed a private placement with New Seneca Partners in March 2026. Vivos continues to emphasize its FDA-cleared technologies as alternatives to traditional OSA treatments.

Latest updates

Vivos Therapeutics Revenue Up, Losses Widen Amid Strategic Shift

Event summary

  • Vivos Therapeutics reported full-year 2025 revenue of $17.5 million, a 16% increase year-over-year.
  • The company’s operating loss for 2025 was $19.9 million, compared to $11.2 million in 2024.
  • Vivos acquired The Sleep Center of Nevada in June 2025, contributing to increased revenue but also higher operating expenses.
  • The company has augmented its cash position with $6.8 million in financing subsequent to year-end.

The big picture

Vivos Therapeutics is undergoing a significant strategic shift, moving away from a dentist-training model to a provider acquisition strategy. While this pivot has initially boosted revenue, it has also resulted in increased operating losses due to integration costs and upfront investments. The company's long-term success depends on its ability to execute this new model effectively and achieve profitability, a challenging task given the current financial performance.

What we're watching

Cash Burn
The company's recent financing provides a short-term buffer, but the widening operating loss necessitates careful monitoring of cash burn and the ability to achieve profitability by year-end as management projects.
Integration Risk
The integration of The Sleep Center of Nevada continues to drive costs; the success of this strategy hinges on realizing synergies and efficiencies beyond revenue gains.
VIP Transition
The wind-down of Vivos Integrated Practice (VIP) enrollment revenue presents a challenge, and the company's ability to replace this revenue stream through acquisitions and alliances will be crucial for sustained growth.

Vivos Therapeutics to Detail 2025 Results Amid Cash Burn Concerns

Event summary

  • Vivos Therapeutics will release its full-year 2025 financial results after market close on April 15, 2026.
  • A conference call is scheduled for 5:00 pm ET on April 15, 2026, to discuss the results and operational updates.
  • Management will address strategic collaborations and their impact on near-term revenue growth and cash burn.
  • Vivos’ CARE devices are FDA-cleared for OSA treatment in both adults and children (ages 6-17).

The big picture

Vivos Therapeutics operates in a large, underserved market for sleep apnea treatment, but faces challenges in achieving profitability. The company's reliance on strategic collaborations and acquisitions to drive growth introduces execution risk, and the forward-looking statements regarding cash flow positivity require close monitoring. The company's unique CARE device technology represents a potential differentiator, but its success hinges on broader adoption and favorable regulatory conditions.

What we're watching

Financial Health
The disclosed cash burn rate will be a key indicator of Vivos’ ability to sustain operations given the company's stated goal of achieving cash flow positivity, and will reveal the effectiveness of recent strategic collaborations.
Collaboration Impact
The actual revenue impact of strategic collaborations will need to be substantial to offset ongoing cash burn and demonstrate a viable path to profitability.
Regulatory Risk
Increased regulatory scrutiny within the sleep apnea treatment sector could impact Vivos’ ability to expand its market share and maintain its current FDA clearances.

New Seneca Partners Doubles Down on Vivos Therapeutics with $2.25M Investment

Event summary

  • Vivos Therapeutics secured a $2.25 million private placement from an affiliate of New Seneca Partners.
  • The deal includes the conversion of a previously announced $1.4 million bridge note, reflecting an original issue discount.
  • Seneca affiliates have invested a total of $13.4 million in Vivos since 2024.
  • The placement included common stock, warrants, and was priced at $1.34 per share.
  • Proceeds will be used for general working capital.

The big picture

New Seneca Partners’ continued investment signals confidence in Vivos’s strategic pivot towards a vertically integrated model encompassing diagnostics and treatment for sleep apnea. The $13.4 million total investment underscores a belief that Vivos is undervalued, despite the challenges inherent in transitioning from a dentist-focused business to a broader healthcare provider network. This move highlights the growing trend of private equity firms backing specialized healthcare services companies focused on chronic disease management.

What we're watching

Operational Efficiency
The company's stated focus on optimizing operations in Las Vegas and Detroit, alongside managing legacy costs, will be critical to achieving the stated breakeven target by the end of 2026 and warrants close monitoring.
Affiliation Model
The success of Vivos’s shift towards a medical affiliation distribution model, as validated by Seneca’s continued investment, hinges on the ability to onboard new practices and integrate them effectively.
Insurance Reimbursement
The sustainability of the ‘in-network’ status recently achieved with commercial health insurance payers and Medicare will significantly impact revenue generation and requires ongoing vigilance.

Vivos Secures Nevada Insurance Coverage, Slashes Costs Amid Distribution Shift

Event summary

  • Vivos Therapeutics’ supported professional practices in Nevada have achieved ‘in-network’ status with a broad range of commercial health insurers and Medicare.
  • The company estimates cost reduction initiatives, including a workforce reduction, will yield approximately $4 million in annualized expense savings.
  • These changes are tied to a shift away from Vivos’ legacy dental-focused distribution model towards a medical affiliation distribution model.
  • The company believes this insurance coverage will significantly impact management services revenue and patient access to its OSA treatments in the Las Vegas market.

The big picture

Vivos’ move to secure in-network insurance coverage represents a significant shift in its business model, moving away from direct-to-patient sales and towards a provider-centric approach. This strategy aims to overcome a key barrier to adoption of its OSA treatments – lack of insurance reimbursement – but introduces new operational and integration risks. The cost reduction initiatives suggest Vivos is proactively addressing potential margin pressure associated with this transition and seeking to accelerate its path to profitability.

What we're watching

Coverage Expansion
The pace at which Vivos secures in-network status in other key markets will be critical to realizing the revenue potential outlined in this announcement.
Execution Risk
How effectively Vivos integrates the acquired sleep centers and manages the transition to its medical affiliation model will determine the long-term success of this strategy.
Financial Impact
Whether the $4 million in estimated cost savings materializes and offsets the potential revenue impact of shifting away from the legacy distribution model remains to be seen.

Vivos Study Bolsters Device Efficacy, Challenges CPAP Dominance

Event summary

  • A study published in the Journal of Clinical Medicine confirms a correlation between oral anatomy (narrow palates, recessed jaws) and the severity of obstructive sleep apnea (OSA).
  • Vivos Therapeutics’ CARE devices have received FDA 510(k) clearance for treating severe OSA in adults and moderate-to-severe OSA in children (ages 6-17), a unique regulatory distinction.
  • The study, involving 100 patients, found a strong association (p<0.001) between craniofacial parameters and OSA severity, as measured by the Apnea-Hypopnea Index (AHI).
  • Vivos estimates that several million Americans will undergo sleep tests annually, with nearly half testing positive for OSA, a market largely served by CPAP.

The big picture

Vivos is positioned to capitalize on a significant unmet need within the sleep apnea treatment market, where CPAP’s high abandonment rate creates an opportunity for alternative, potentially curative, solutions. The company’s FDA clearance and the supporting study provide a strong foundation, but its success hinges on demonstrating long-term efficacy and achieving widespread adoption among both providers and patients. The $30 billion sleep apnea market is ripe for disruption, but Vivos faces an uphill battle against entrenched practices and established competitors.

What we're watching

Market Adoption
The pace at which Vivos CARE devices can displace CPAP as the primary treatment option will depend on provider adoption and patient willingness to transition from a familiar, albeit often problematic, standard of care.
Regulatory Scrutiny
Continued regulatory scrutiny of Vivos’ devices and treatment protocols is likely, particularly given the unprecedented clearance for severe OSA, and could impact commercialization efforts.
Clinical Validation
Further clinical validation of Vivos’ methodology and long-term efficacy data will be critical to solidify its position and attract broader payer coverage.

Vivos Therapeutics Adds AI-Powered Sleep Tech via SoundHealth Collaboration

Event summary

  • Vivos Therapeutics has entered a collaboration with SoundHealth to distribute SoundHealth’s FDA-cleared allergy and sleep technologies.
  • Vivos will resell SoundHealth’s Sonu® Band and Spatial Sleep™ band through its network of over 2,000 dentists and sleep healthcare providers.
  • SoundHealth’s technology utilizes personalized vibro-acoustic neuromodulation and smartphone-based facial scanning and voice biomarker analysis.
  • The collaboration aims to leverage SoundHealth’s large craniofacial dataset to promote airway health awareness and treatment.

The big picture

Vivos’ collaboration with SoundHealth represents a strategic move to expand its product offerings beyond its core CARE devices and capitalize on the growing $30 billion global sleep technology market. The partnership signals a broader trend toward personalized, AI-driven solutions in sleep apnea treatment, moving away from traditional, often less effective, methods like CPAP. SoundHealth’s FDA clearances and TIME ‘Best Inventions’ recognition provide a degree of validation, but the execution risk of integrating a new technology and distribution model into Vivos’ existing operations remains significant.

What we're watching

Market Adoption
The success of this collaboration hinges on Vivos’ ability to effectively integrate SoundHealth’s products into its existing provider network and drive patient adoption, given the relatively nascent stage of active airway intervention in sleep technology.
Data Integration
How Vivos utilizes SoundHealth’s craniofacial dataset and voice biomarker technology to improve diagnostic accuracy and treatment efficacy will be a key differentiator and a potential source of competitive advantage.
Regulatory Scrutiny
As the sleep technology sector shifts towards active interventions, increased regulatory scrutiny of device efficacy and patient safety is likely, which could impact the long-term viability of SoundHealth’s FDA-cleared devices.

Vivos Therapeutics Boosts Cash with Warrant Exercise, Issues New Warrants

Event summary

  • Vivos Therapeutics closed the exercise of outstanding warrants, generating $4.64 million in gross proceeds.
  • The warrants, originally issued in 2023, 2024, and 2026, were exercised at a reduced price of $2.34 per share.
  • In exchange for the cash, Vivos issued new unregistered warrants to purchase up to 3,964,712 shares at an exercise price of $2.09 per share.
  • The company intends to use the net proceeds for working capital and general corporate purposes.

The big picture

Vivos' financing activity underscores the ongoing need for capital to support its growth strategy in the sleep apnea market, a sector with significant unmet needs but also facing increasing competition and regulatory scrutiny. The issuance of new warrants, while providing immediate funding, introduces a layer of complexity regarding future shareholder dilution and potential liquidity impacts. The company's reliance on acquisitions and collaborations to expand its reach also presents execution risks that investors should monitor.

What we're watching

Dilution Risk
The issuance of new warrants introduces potential future dilution for existing shareholders, contingent on their exercise, which warrants further scrutiny of the company's capital structure.
Registration Timeline
The timing of the SEC registration of the shares issuable upon exercise of the new warrants will be critical, as it dictates when those shares can be freely traded and impacts liquidity.
Working Capital Use
Vivos' ability to effectively deploy the working capital gained from this financing to accelerate growth and achieve profitability will be a key indicator of management's execution capabilities.

Vivos Therapeutics Boosts Cash with Warrant Exercise, Issues New Warrants

Event summary

  • Vivos Therapeutics has received approximately $4.64 million in gross proceeds from the exercise of outstanding warrants.
  • The warrants, originally issued in 2023 and 2024, were exercised at a reduced price of $2.34 per share.
  • In exchange, Vivos issued new unregistered warrants to purchase up to 3,964,712 shares at an exercise price of $2.09 per share.
  • The offering is expected to close on January 20, 2026, and proceeds will be used for working capital and general corporate purposes.
  • The new warrants will be registered for resale, and Vivos intends to file a registration statement with the SEC.

The big picture

This financing event suggests Vivos is actively seeking capital to support its growth initiatives, potentially including acquisitions or expansion of its CARE device program. The warrant structure, while providing immediate funding, introduces a layer of complexity with potential future dilution. The company's reliance on private placements and the need for SEC registration highlights the challenges of raising capital for specialized medical device companies, particularly those with a relatively narrow market focus.

What we're watching

Share Dilution
The issuance of new warrants will dilute existing shareholders, and the eventual exercise of these warrants could further impact ownership structure and per-share value.
Registration Timeline
The speed with which Vivos files and gains approval for the registration statement covering the new warrants will dictate when those shares can be freely traded, impacting liquidity and potential price volatility.
Capital Allocation
How effectively Vivos utilizes the $4.64 million in proceeds for working capital and general corporate purposes will be a key indicator of its operational efficiency and ability to drive future growth.
CID: 573